What is the recommended management of hypercalcemia?

Hypercalcemia Treatment

For acute symptomatic or severe hypercalcemia (≥14 mg/dL or ≥3.5 mmol/L), immediately initiate aggressive IV hydration with normal saline followed by IV bisphosphonates (zoledronic acid preferred) or denosumab; for severe cases requiring rapid calcium reduction, add calcitonin to the initial regimen. 1, 2

Initial Assessment and Severity Classification

Measure albumin-corrected total calcium and ionized calcium to determine severity:

• Mild: Total calcium <12 mg/dL (<3 mmol/L) or ionized 5.6-8.0 mg/dL - usually asymptomatic
• Severe: Total calcium ≥14 mg/dL (≥3.5 mmol/L) or ionized ≥10 mg/dL (≥2.5 mmol/L) - causes nausea, vomiting, confusion, somnolence, coma 2

Check intact PTH immediately to distinguish:

• PTH elevated or normal: Primary hyperparathyroidism
• PTH suppressed (<20 pg/mL): Malignancy or other PTH-independent causes 2

Acute Management Algorithm

Step 1: Hydration (All Symptomatic Cases)

• IV normal saline as first-line therapy for volume repletion 1, 2
• After correcting hypovolemia, consider loop diuretics (furosemide) only if needed for volume overload 3
• Critical caveat: Do NOT use loop diuretics before adequate hydration - this worsens hypercalcemia

Step 2: Antiresorptive Therapy

The 2023 Endocrine Society guideline recommends denosumab over IV bisphosphonates for hypercalcemia of malignancy (conditional recommendation), though both are effective 1. Key considerations:

Denosumab advantages:

• Lower renal toxicity - preferred in renal disease 4, 1
• Effective for bisphosphonate-refractory cases 1
• Works within 2-3 days 3

IV Bisphosphonates (zoledronic acid or pamidronate):

• Zoledronic acid specifically preferred for hypercalcemia treatment 4
• Category 1 recommendation in multiple myeloma 4
• Works within 2-3 days 3
• Monitor renal function - avoid in severe renal impairment 4

Step 3: Adjunctive Rapid-Acting Therapy

For severe hypercalcemia requiring immediate calcium reduction:

• Add calcitonin to bisphosphonate or denosumab as initial combination therapy 1
• Calcitonin works within hours but has tachyphylaxis 3
• The guideline suggests this combination specifically for severe cases (conditional recommendation) 1

Etiology-Specific Management

Malignancy-Related Hypercalcemia

• Treat underlying malignancy - instrumental for controlling hypercalcemia and preventing recurrence 1
• Use denosumab or IV bisphosphonate as above
• Poor prognosis - associated with advanced disease 2

High Calcitriol States (Lymphomas, Granulomatous Disease)

• Glucocorticoids (prednisone) as primary treatment for excessive intestinal calcium absorption 2, 5
• Add IV bisphosphonate or denosumab if glucocorticoids alone insufficient and hypercalcemia remains severe/symptomatic 1

Parathyroid Carcinoma

• Use either calcimimetic (cinacalcet) or antiresorptive (IV bisphosphonate/denosumab) 1
• Cinacalcet can effectively reduce calcium within 2-3 days 3

Primary Hyperparathyroidism

• Mild, asymptomatic cases in patients >50 years with calcium <1 mg above upper limit and no skeletal/kidney disease: Observation acceptable 2
• Symptomatic or meeting surgical criteria: Parathyroidectomy is curative 2
• Excellent prognosis with either medical or surgical management 2

Refractory Cases

If hypercalcemia persists despite bisphosphonates:

• Switch to denosumab - two-thirds achieve resolution 6
• Consider hemodialysis with calcium-free dialysate for patients with renal failure or truly refractory severe hypercalcemia 5, 3

Critical Monitoring

• Baseline dental examination before starting bone-modifying agents 4
• Monitor for osteonecrosis of jaw (ONJ) - occurs in 2-3% with denosumab/bisphosphonates 4
• Monitor for hypocalcemia - higher risk with denosumab 4
• Monitor renal function with bisphosphonates 4

Common Pitfalls to Avoid

• Do not delay treatment for extensive diagnostic workup in severe symptomatic hypercalcemia 3
• Do not use loop diuretics before volume repletion - worsens hypercalcemia
• Do not assume mild hypercalcemia is benign - 20% have constitutional symptoms requiring intervention 2
• Do not continue bisphosphonates indefinitely - in multiple myeloma, continue up to 2 years then reassess 4